Summary of safety profile: The administration of perindopril inhibits the renin-angiotensin-aldosterone axis and tends to reduce the potassium loss caused by indapamide.
The most commonly reported adverse reactions observed are: With perindopril: dizziness, headache, paresthesia, dysgeusia, visual impairment, vertigo, tinnitus, hypotension, cough, dyspnea, abdominal pain, constipation, dyspepsia, diarrhea, nausea, vomiting, pruritus, rash, muscle cramps and asthenia.
With indapamide: hypersensitivity reactions, mainly dermatological, in subjects with a predisposition to allergic and asthmatic reactions and maculopapular rashes.
5 mg/1.25 mg: Four percent of the patients on treatment with Perindopril arginine + Indapamide (Coversyl Plus) 5mg/1.25mg experience hypokalemia (potassium level < 3.4 mmol/l).
10 mg/2.5 mg: Six percent of the patients on treatment with Perindopril arginine + Indapamide (Coversyl Plus) 10mg/2.5mg experience hypokalemia (potassium level < 3.4 mmol/l).
Tabulated list of adverse reactions: The following undesirable effects have been observed during clinical trials and/or post-marketing use and ranked under the following frequency: Very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1000, <1/100); rare (≥1/10000, <1/1000), very rare (<1/10000), not known (cannot be estimated from the available data). (See Tables A and B.)


Reporting of Adverse Drug Reaction: For suspected adverse drug reaction, report to the FDA at www.fda.gov.ph.
Seek medical attention immediately at the first sign of any adverse drug reaction.
View ADR Reporting Link